Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 12, 2002, Pages 674-682

  Remberger, Mats ^a   Kumlien, Gunilla ^a   Aschan, Johan ^a   Barkholt, Lisbeth ^a   Hentschke, Patrick ^a   Ljungman, Per ^a   Mattson, Jonas ^a   Svennilson, Johan ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic graft versus host disease; Stem cell transplantation

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CHILD; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD ASSESSMENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; LIVING DONOR; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEWBORN; RECIPIENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; WHOLE BODY RADIATION;

EID: 12244290591     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.abbmt080674     Document Type: Review

References (53)

1. Lister J, Messner H, Keystone E, Miller R, Fritzler MJ. Autoantibody analysis of patients with graft-versus-host disease. J Clin Lab Immunol. 1987;24:19-23.
2. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and scleroderma. Br J Haematol. 1987;66:45-47.
3. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57: 267-276.
4. Atkinson B, Storb R, Prentice RL, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood. 1979;53:720-731.
5. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol. 1985;13:1062-1067.
6. Atkinson K, Horowitz M, Van Bekkum DW, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-2464.
7. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical sibling. Ann Intern Med. 1983;98:461-466.
8. Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood. 1989;75:555-562.
9. Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogencic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;18:921-929.
10. Weiden P, Flournoy N, Thomas E, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogenic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
11. Vogelsang G, Santos G, Colvin O, Chen T. Thalidomide for graft-versus-host disease [letter]. Lancet. 1988;1:827.
12. Besnier DP, Chabannes D, Mahe B, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation. 1997;64:49-54.
13. Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med. 1980;69:204-217.
14. Lee S, Klein J, Barret J, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2001;98:3205-3211.
15. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41:1299-1305.
16. Ringdén O, Båryd I, Johansson B, et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radiol Oncol. 1983;22: 423-428.
17. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipients with leukemia. Blood. 1994;83:2723-2730.
18. Ringdén O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate: a randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant. 1991;7:221-226.
19. Ringdén O, Groth C, Aschan J, et al. Bone marrow transplantation for metabolic disorders at Huddinge Hospital. Transplant Proc. 1990;22:198-202.
20. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995;15:619-625.
21. Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation. 1995;60:1225-1230.
22. Thomas E, Storb R, Clift R, et al. Bone-marrow transplantation, I and II. N Engl J Med. 1975;292:832-843.
23. Storb R, Epstein R, Graham T, Thomas E. Methotrexate regimens for control of graft-versus-host disease in dogs with allogenic marrow grafts. Transplantation. 1970;9:240-246.
24. Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant. 1986; 1:41-51.
25. Deeg H, Storb R, Appelbaum F, et al. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation. 1984;37:62-65.
26. Storb R, Deeg H, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
27. Aschan J, Ringdén O, Andström E, Ljungman P, Lönnqvist B, Remberger M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant. 1994;14:79-87.
28. Carlens S, Aschan J, Remberger M, Dilber MS, Ringdén O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant. 1999;24:629-635.
29. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555-561.
30. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-554.
31. Hymes SR, Morison WL, Farmer ER, Walters LL, Tutschka PJ, Santos GW. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol. 1985;12:30-37.
32. Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug- resistant chronic graft-versus-host disease. Transplantation. 1990;49:657-658.
33. Ljungman P, Plotkin S. Workshop on CMV disease: definition, clinical severity scores, and new syndromes. Scand J Infect Dis Suppl. 1995;99:87-89.
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
35. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
36. Cox D. Regression models and life-tables. J R Stat Soc [Ser B]. 1972;34:187-220.
37. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid- refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426-2431.
38. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755-761.
39. Boström L, Ringdén O, Jacobsen N, Zwaan F, Nilsson B. A European multicenter study of chronic graft-versus-host disease. Transplantation. 1990;49:1100-1105.
40. Muller-Hermelink HK, Sale GE, Borisch B, Storb R. Pathology of the thymus after allogeneic bone marrow transplantation in man: a histologic immunohistochemical study of 36 patients. Am J Pathol. 1987;129:242-256.
41. Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of graft-versus-host-induced severely dysplastic thymuses: implications for the pathogenesis of chronic graft- versus-host disease. Am J Pathol. 1988;133:39-46.
42. Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant. 1995;1:18-23.
43. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994;152:1609-1617.
44. Balkwill FR. Interferons. Lancet. 1989;1:1060-1063.
45. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-1061.
46. Lee SJ, Klein JP, Anasetti C, et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001;98:3205-3211.
47. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-2990.
48. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394-401.
49. Carlens S, Ringdén O, Aschan J, et al. Risk factors in bone marrow transplant recipients with leukaemia: increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant. 1998;12:84-92.
50. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397-406.
51. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Alloimmunity to human H-Y. Lancet. 1976;2:1206.
52. Lönnqvist B, Ringdén O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding graft-versus-host disease. Transplantation. 1984;38:465-468.
53. Söderberg C, Larsson S, Lundh Rozell B, Sumitran-Karuppan S, Ljungman P, Möller E. Cytomegalovirus-induced CD13-specific autoimmunity: a possible cause of chronic graft-versus-host disease. Transplantation. 1996;61:600-609. f